News

This guide includes everything you need to know about amantadine (Osmolex ER, Osmotica Pharmaceuticals) for the treatment of Parkinson disease and drug-induced extrapyramidal reactions in adults.

A new research project is underway to improve the pre-surgical evaluation of pediatrics with medical refractory epilepsy.

The section chief of pediatric neurology at Nationwide Children’s Hospital shared his excitement about the approval of Epidiolex and its potential as a therapeutic.

Previous analysis has suggested that an extended dosing regimen can reduce the risk of progressive multifocal leukoencephalopathy for patients with relapsing multiple sclerosis.

This guide includes everything you need to know about cannabidiol (Epidiolex, GW Pharmaceuticals) for the treatment of 2 rare types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures.

If a larger set of samples can be used to test the 3 metabolites identified, the researchers note that they can validate the findings and develop a saliva test for Alzheimer disease.

This guide includes everything you need to know about pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of delusions and hallucinations associated with Parkinson disease psychosis.

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.

Final approval is expected by June 20, 2020, ahead of the generic erosion following the patent expiration of Biogen’s Tecfidera.

The professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.

This guide includes everything you need to know about erenumab-aooe (Aimovig, Amgen/Novartis) for the preventive treatment of migraine in adults.

The anti-CD20 antibody showed greater reductions in Expanded Disability Status Scale scores over a decade in patients with SPMS compared to matching controls never treated with it.

This guide includes everything you need to know about fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis in adults and children.

The Clinical Director of the NHGRI spoke about the impact of the NIH program and its future development.

The director of the sleep clinic and assistant professor of neurology at Harvard Medical School discussed what has been learned about pediatric narcolepsy in the last decade, as well as what questions remain unanswered.

This guide includes everything you need to know about subcutaneous immunoglobulin (Hizentra, CSL Behring) in the treatment of chronic inflammatory demyelinating polyneuropathy as well as primary immunodeficiency.

Neurology News Network for the week of January 5, 2019.

The director of the Jefferson Comprehensive Epilepsy Center and the Jefferson Clinical Neurophysiology Laboratory spoke to the therapy’s success thus far.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

The head of the Children’s Brain Dynamics Laboratory at Boston Children’s Hospital discussed the HOPE project and its goals moving forward.

The FDA notice stated that these discontinuations are the result of a business decision by manufacturer GlaxoSmithKline.

In case you missed the recent publication of these books, they are presented here for your library. Is there a recent book missing from this list you’d like to review, let us know!

The director of the sleep clinic and assistant professor of neurology at Harvard Medical School spoke about the state of pediatric narcolepsy management and diagnosis.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.

The director of the Jefferson Comprehensive Epilepsy Center and the Jefferson Clinical Neurophysiology Laboratory provided insight about the phase 3 safety trial of cenobamate.

A proof-of-concept trial’s findings have shown that more clinical research into the potential neuroprotective effect of cannabinoids in slowing disease progression in motor neuron disease is warranted.